The eMESH 1 Feasibility Study

Kips Bay Medical, Inc.120 enrolled

Overview

Multi-center, dual cohort (randomized and single vessel) study designed to demonstrate feasibility, initial safety and performance of the Kips Bay Medical, Inc. eSVS® Mesh as an external vein support device for use over saphenous vein grafts during coronary artery bypass surgery. In the Randomized Cohort, each study subject will receive a SVG without Mesh (control) and a SVG with the eSVS Mesh (treatment). In the Single Vessel Cohort, each study subject will receive one SVG with the eSVS Mesh.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

120

Conditions

Atherosclerosis of Autologous Vein Coronary Artery Bypass Graft(s)

Interventions

eSVS Mesh treated saphenous vein graftDEVICE

During coronary artery bypass graft surgery, one SVG will be randomized to be treated with eSVS Mesh and implanted in the right or left coronary system.

Control saphenous vein graftOTHER

During coronary artery bypass graft surgery, one SVG will be randomized to be the control (no eSVS Mesh) and implanted in the right or left coronary system.

Eligibility

Sex: ALLMin age: 21 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Randomized Cohort: Requires CABG surgery with a SVG to the right coronary artery (RCA) system AND the left circumflex artery (LCX) system with a ≥ 70% stenosis in each of the two systems. * Single Vessel Cohort: Requires CABG surgery with a SVG to the RCA system or the LCX system with a \> 70% stenosis in the system. * Medial sternotomy with cardiopulmonary bypass (CPB) during surgery. * Both saphenous vein graft length are adequate for planned intervention, vein outer diameter is between 3.6 mm and 7.0 mm and double wall thickness less than 1.4 mm. * Agreement to post-procedure follow-up contact and testing (including follow-up coronary angiogram). Exclusion Criteria: * Concomitant non-CABG cardiac procedure. * Prior cardiac surgery (does not include percutaneous procedures). * Cerebrovascular or transient ischemia attack within 30 days of the CABG procedure. * Age \> 85 years. * Left ventricular ejection fraction ≤ 35%. * Creatinine \> 133 μmol/L (1.5 mg/dL) prior to CABG procedure or on chronic dialysis. * STEMI within 7 days or total CK \> 2 times the upper limit of normal prior to the CABG procedure. * Both enrolled grafts will feed non-viable myocardial territory. * Diffuse atherosclerotic disease (\> 70%) distal to either of the enrolled target coronary arteries. * Randomized Cohort: By visual estimate, the target coronary artery diameter of both the right coronary system and left circumflex system must be within 1.5mm of each other. * Planned endarterectomy of the target coronary artery.

Locations (15)

Emory University Hospital Midtown

Atlanta, Georgia, United States

RECRUITING

Northeast Georgia Heart Center

Gainesville, Georgia, United States

Outcomes

Primary Outcomes

MACE

The rate of major adverse coronary events (MACE) defined as the rate of the composite of total mortality, MI (Q wave and non Q wave), and/or coronary target vessel revascularization (percutaneous coronary intervention or CABG).

Time frame: 30 days

SVG patency determined by angiography

Angiographic patency rate of the enrolled grafts defined as \< 50% stenosis.

Time frame: 6 months

Technical success implanting eSVS Mesh

Technical success defined as successful placement of the eSVS Mesh on the saphenous vein and surgical implantation of the SVG.

Time frame: intra-operative

Secondary Outcomes

MACCE and mediastinitis

MACE, MACCE, MI and all mortality rates through five years, mediastinitis rate through 6 months.

Time frame: 5 years

SVG patency determined by angiography

Angiographic patency rate of the enrolled grafts defined as \< 75%.

Time frame: 6 months

Plaque burden

Plaque burden of the enrolled grafts as assessed by IVUS imaging (IVUS Sub-Study).

Time frame: 6 months

Central Contacts

Rebecca Wetterling

CONTACT

763-235-3540 clinical@kipsbaymedical.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.